uate the analytical performance of molecular methods have been proposed as an alternative (4 -10 ) .
The EQUAL Project ["MultiNational External Quality Assay (EQA) Programs in Clinical Molecular Diagnostics Based on Performance and Interpretation of PCR Assay Methods"], proposed under the auspices of the EC4 and funded by the European Commission, was designed to evaluate the implementation of molecular diagnostics relevant to all laboratories. Three methodological EQA programs have been implemented: EQUAL-qual for qualitative PCR assays, EQUAL-quant for quantitative PCR assays, and EQUAL-seq for sequencing-based assays. Results from the EQUAL-quant and the EQUAL-seq programs have been described (5, 6 ) .
This report describes the results of EQUAL-qual, which aims to provide a critical assessment of performance of laboratories in DNA extraction and/or amplification. The program requires participating laboratories to send aliquots of their samples back to a central reference laboratory (EQUAL-Laboratory) for a standardized analysis.
Materials and Methods experimental design
The features of the EQUAL-qual program were diffused by Web site advertisements (http://www.ec-4.org/ equal); 213 laboratories, from 25 countries, registered to participate (see Table 1 in the Data Supplement that accompanies the online version of this article at http:// www.clinchem.org/content/vol53/issue7). At registration, a random confidential code number was assigned to each laboratory, as well as a password for all the following steps of data communication.
Each participant laboratory received an express mail package, to be stored at 4°C, containing 6 vials: 2 contained 1.2 mL of a pool of human whole blood, citrate anticoagulated (HIV negative and hepatitis B virus negative), indicated as sample 1 (female; leukocytes ϭ 3.8 ϫ 10 9 /L) and sample 2 (male; leukocytes ϭ 4.4 ϫ 10 9 /L); sample 3 contained 50 L pre-extracted DNA prepared by the salting-out procedure (11 ) from a pool of leukocytes taken from healthy male volunteers and resuspended to a concentration of 20 ng/L; sample 4 contained 50 L pre-extracted DNA from a pool of leukocytes taken from healthy female volunteers and resuspended to a concentration of 50 ng/L. In addition, sample 4 was enriched with 0.04% BSA to produce an artificial decrease of 260:280 ratio to ϳ1.4. Two complete primer mixes at 20 mol/L were also included (vials 5 and 6).
primers
Primer set A contained primers to amplify the human growth hormone gene (GH1, 12 actions Participants received detailed instructions for actions to be performed using the samples of the EQA package (see Table 2 in the online Data Supplement), as well as a complete questionnaire (see Table 3 in the online Data Supplement) on the relevant features of laboratory structure.
preamplification phase
Participants were requested to perform DNA extraction by the procedure routinely used in their laboratory. DNA quality and quantity were estimated by the participants in all samples: the 2 blood-derived extracts (samples 1 and 2) and the 2 pre-extracted DNA samples (samples 3 and 4). Participants were asked to provide the following information:
For participants unable to provide the 320-nm absorbance readings, 260 and 280 nm were deemed sufficient.
amplification phase
Participants were asked to set up a PCR with 100 ng DNA (as calculated by participants) from samples 1, 2, 3, and 4 and a water control with primer sets A and B. Participants were instructed to use Taq polymerase, dNTPs, and other reagents commonly in use in their own laboratory at the concentration used for a routine amplification under the following suggested PCR conditions: primer concentration set A, 0.25 mol/L; primer concentration set B, 0.5 mol/L; PCR conditions, 94°C for 30 s, 60°C for 30 s, 72°C for 60 s (40 cycles).
data submission
Participants were required to submit the raw data from DNA quantification and post-PCR interpretation (number and size of amplified targets) by means of the dedicated Web site. In addition, in an express mail shipment box provided by the project, participants sent an aliquot of each PCR product and aliquots of DNA extracted from samples 1 and 2 to the EQUAL-Laboratory for further analysis.
reevaluation of samples in equal-laboratory
In EQUAL-Laboratory, the quality (R) and the quantity (Q) of DNA extracts obtained from blood samples 1 and 2 were reevaluated by use of the full-spectrum (220 -750 nm) spectrophotometer NanoDrop ® ND-1000 (NanoDrop Technologies). The values obtained in the EQUAL-Laboratory are indicated as Re and Qe, respectively. The products of PCR amplification were analyzed in EQUALLaboratory using the Agilent 2100 Bioanalyzer (Agilent Technologies) to provide a standardized estimation of the size and quantity of the PCR products (efficiency of amplification ϭ E). The yield of each PCR product was assessed, corrected for PCR volume, and expressed in terms of ng DNA per amplified target.
statistical methods
In the absence of known reference values for each of the factors investigated, we measured the consistency of a given participant's results against the majority (90%) of the results provided by the other participants. We adopted a statistical distribution-free approach to process the highly positively skewed data arising from this quality control program. We analyzed data according to a 2-step procedure aiming to (a) detect outliers and/or (b) identify laboratories with issues of poor performance. The 1st step involves the computation of the 95th bootstrap centile (14 ) of the distribution of the absolute value of the M statistic (15 ) . This centile was adopted as the threshold to detect outliers. After removing the outliers (ϳ5%) from the analysis, we identified poor-performing laboratories by computing the 2 thresholds: 2.5th and 97.5th bootstrap centile of the original measurements. In each case, the number of bootstrap samples was 1000.
In the preamplification phase, the variables available for statistical analysis were Q (Q1-Q4) and R (R1-R4), provided by each laboratory for all 4 samples, and Qe (Qe1, Qe2) and Re (Re1, Re2), measured by the EQUALLaboratory for samples 1 and 2 only. In addition, for samples 1 and 2, we calculated the difference between the individual participant measurements and those obtained by the EQUAL-Laboratory as ⌬Q ϭ Qe Ϫ Q (⌬Q1, ⌬Q2) and ⌬R ϭ Re Ϫ R (⌬R1, ⌬R2). Thus a total of 16 variables were processed.
Because samples of poor DNA quality (R) will give unreliable estimates of DNA quantity (Q), we investigated Q only after removing laboratories from the analysis with questionable measurements for R. We processed all the variables according to the 2-step procedure described above.
To assess PCR efficiency (E), 10 measurements yielded by EQUAL-Laboratory were available for analysis. Five of these (E1-E5) were obtained from blood samples and 5 from pre-extracted DNA samples (E6 -E10). Considering these 2 data sets individually, we generated a score by incorporating all 5 measurements. We adopted principal component (PC) analysis (16 ) to evaluate overall laboratory performance. This technique involves the computation of uncorrelated new variables, the PCs, which are ordered so that the 1st retains most of the variation present in all of the original data and the level of importance decreases by moving from the 1st to the last PC. Specifically, the PCs can be thought of as k new variables, obtained as a linear combination of the k original variables. Consequently, for each PC a set of k specific coefficients is defined, and with a small number of original variables, as in this case, the coefficients of the 1st PC are expected to have the same sign. Therefore if, for a given laboratory, all the measurements are lower than the respective means, that laboratory will have a low score for the 1st PC; conversely, if all the measurements are higher than the respective means, it will have a high score for the 1st PC. Therefore the 1st PC identifies laboratories that tend to systematically over-or underestimate the amplification product (quantified by E) with respect to the mean. To assess the overall performance level of each laboratory, we processed the score according to the 2-step approach described above.
We performed statistical analyses with the SAS System (17 ).
Results participants
A brief description of some features of the participant laboratories is listed in Table 4 in the online Data Supplement.
preamplification phase
Among the 175 laboratories that completed the survey, 9 did not provide data on DNA quality and quantity for all the samples because this procedure was not routinely used in their laboratories; 1 laboratory did not provide data on DNA quantity and quality for sample 3, and 1 laboratory did not provide these measurements for the 2 pre-extracted DNA samples. Table 1 shows a summary of the preamplification results. Table 5 , A-D, in the online Data Supplement reports the identification code (IDlaboratory) of laboratories with outlying measurements or issues of poor performance (laboratories for which at least 1 questionable result was observed).
DNA quality. The median quality (see Table 1 ) of extracted DNA in blood samples 1 and 2 (R1 and R2) was constant and similar to that measured in pre-extracted DNA (R3), as confirmed from the overlapping of the interquartile range (IQR; 75th centile to 25th centile). In 21 of 166 laboratories (13%), however, we identified questionable Clinical Chemistry 53, No. 7, 2007 results for either R1 or R2 (see Table 5A in the online Data Supplement), indicating suboptimal extraction protocols and/or incorrect photometric measurements. Moreover, 16 of 164 laboratories (10%) provided questionable results for R3 and 17 of 165 (10%) for R4 (see Table 5B in the online Data Supplement). Because these factors correspond to pre-extracted DNA samples, these results are most likely the result of erroneous photometric measurements. Eight laboratories provided questionable results in both blood and pre-extracted DNA, suggesting a possible technical problem common to both analyses.
DNA quantity. The median and IQRs for quantities of DNA extracted from blood samples 1 and 2 (Q1 and Q2) were similar and close to those measured in pre-extracted sample 3 (Q3). Among laboratories with results of acceptable quality, some laboratories reported anomalous results for DNA quantity evaluation in blood samples (see Table 5A in the online Data Supplement). In particular, questionable results were identified in 15 laboratories (3 below the 2.5th centile and 12 above the 97.5th centile) for Q1 and in 14 laboratories (3 below the 2.5th centile and 11 above the 97.5th centile) for Q2. Even for these factors, the presence of anomalous results was also evident in preextracted DNAs (see Table 5B in the online Data Supplement), with anomalous performances in 13 laboratories (3 below the 2.5th centile and 10 above the 97.5th centile) for Q3 and in 16 laboratories (4 below the 2.5th centile and 12 above the 97.5th centile) for Q4.
Comparison with results of EQUAL-Laboratory. Participants were asked to return an aliquot of the DNA extracts from blood samples 1 and 2 for evaluation in the central EQUAL-Laboratory. Table 1 shows that the median values for ⌬R1 and ⌬R2 are closer to 0 (the expected value) than the corresponding values for ⌬Q1 and ⌬Q2. The results in Table 5 , C and D, in the online Data Supplement report the laboratories for which at least 1 questionable measurement was observed during this reevaluation. Twenty-seven laboratories share anomalous results in panels C and D, indicating simultaneous problems for DNA extraction and evaluation. In the 19 laboratories included only in panel C, the presence of questionable performances due to bad DNA extraction from blood samples 1 and 2 can be postulated. Conversely, in the 18 laboratories included only in panel D, the differences with values by EQUAL-Laboratory seem to be due to abnormalities in photometric evaluation.
amplification phase
Efficiency of amplification. We assessed efficiency of amplification (E) by reanalyzing the PCR products returned by each participant to the EQUAL-Laboratory. With the PC analysis described, only laboratories able to provide a complete data set were considered in the analysis (163 blood samples and 167 DNA pre-extracted samples). Table 2 shows the minimum, median, maximum, and IQR for the 10 measurements.
In PC analysis, the 1st PC accounts for 82% and 74% of the total variability for blood and pre-extracted DNA measurements, respectively. Therefore, the 1st component captures almost the total information given by each set of 5 measurements. The pertinent scores were computed according to the following linear combinations: the quantity of DNA extracted from blood samples 1 and 2 (mg/L) obtained from ͓(260 nm Ϫ 320 nm) ϫ 50 ϫ dilution factor ϫ DNA reconstitution volume)/extracted blood volume͔ or directly measured in pre-extracted samples 3 and 4, respectively. Re1 and Re2 are the (260 nm Ϫ 320 nm)/(280 nm Ϫ 320 nm) ratios measured in the EQUAL-Laboratory by Nanodrop in blood samples 1 and 2, respectively, as provided by participants. Qe1 and Qe2 are the DNA quantities measured in the EQUAL-Laboratory with Nanodrop in blood samples 1 and 2, respectively, as provided by participants.
Blood samples: score ϭ
Pre-extracted DNA samples: score ϭ
Because the coefficients of the linear combinations have the same sign and are similar, the load of each measurement in defining the score is almost the same. Consequently, the identification of poor-performing laboratories by means of the 1st PC as suggested in Statistical Methods is valid.
Each panel (A-E) of Figs. 1 and 2 shows a box-plot graph for single measurements of blood samples and pre-extracted DNA samples, respectively. The scores enable us to identify laboratories that report measurements outside of the 10th or 90th centile of the original distribution on at least 3 occasions. Five laboratories showed very low levels of PCR amplification from extracted DNA samples (Fig. 1) , and in 3 of those laboratories this was replicated with the pre-extracted DNA (Fig. 2) , indicating generalized problems of PCR performance. Conversely, some laboratories showed high PCR efficiency, over the limit of the right arm (90th centile); in 5 cases, the data were deemed unusually high, suggesting possible mistakes in protocol execution.
Number of bands of amplified targets. As indicated above, primer set A generated an amplification product of 427 bp, and primer set B generated amplification products of 105 bp on chromosome Y and of 290 bp on chromosome X. Therefore, we expected a single product when using primer set A against all 4 samples (C1A, C2A, C3A, C4A), a single product with primer set B against samples 1 and 4 (C1B and C4B), and 2 PCR products in DNA samples 2 and 3 (C2Bl, C2Bu, C3Bl, C3Bu). Table 3 shows the laboratories (18 of 175; 10%) that did not report the expected number of fragments for primer sets A and/or B. Table 3 also shows the nature of the error (higher or lower number of bands than expected), the bands for which these errors were detected, whether the errors were confirmed by reevaluation of the PCR products at EQUAL-Laboratory, and finally an interpretation of the possible source of the errors. Five laboratories reported the wrong number of bands when the correct number of bands was obtained in the EQUAL-Laboratory, presumably owing to either data transcription errors or mistakes in the electrophoresis interpretation. Eight laboratories reported a lower number of bands than expected, possibly owing to insufficient PCR efficiency. In 6 of those results, the lack of the bands was confirmed in the EQUAL-Laboratory analysis; in the remaining 2 results a low but detectable band was obtained. The other 5 laboratories reported a higher number of bands than expected, probably owing to contamination of the PCR or a nonoptimized PCR protocol. In 1 laboratory, the presence of the contamination was confirmed by the EQUAL-Laboratory analysis, whereas contamination was not confirmed for the remaining 4 laboratories, suggesting possible contamination of the sample during a post-PCR procedure such as loading of the gel.
Discussion
Aspects of good laboratory practice are essential to both preanalytical and analytical phases of nucleic acid amplification (18, 19 ) . The EQUAL-qual project was designed to evaluate laboratory performance by 2 means: 1st, on the basis of data directly reported by participants (quantity and quality of DNA, number of amplicons after gel electrophoresis), and 2nd, on the basis of data obtained by the reevaluation of samples in the EQUAL-Laboratory. This 2nd step was designed to identify mistakes due to manual or conceptual errors during the implementation of the exercise (dilution, calculation, reporting, etc.) or to imperfect functioning of reagents or instruments (such as photometers and apparatus for gel electrophoresis). Dif- The results of the preamplification phase have been evaluated to address 2 major aspects: (a) performance of photometric measurements for DNA quality and quantity Each panel shows a box-plot graph for single measurements (expressed in terms of ng DNA per amplified products) for blood samples. The box shows the 25th and 75th centiles, the vertical line inside the box indicates the median, and the limits of the 2 arms correspond to the 10th and 90th centiles. Black circles identify laboratories with outlier measurements; white circles identify laboratories with issues of poor performance. E1, sample 1/primer set A; E2, sample 2/primer set A; E3, sample 1/primer set B; E4, sample 2/primer set B/lower band product; E5, sample 2/primer set B/upper band product.
and (b) performance of the blood extraction procedure in terms of the amount and quality of the extracted DNA (see Table 1 ; see Table 5 in the online Data Supplement). The 2 pre-extracted DNA samples were used to estimate the reliability of conventional photometric measurements.
Twenty-five percent of laboratories (42 of 165) performed poorly in the quantification of at least 1 of the 2 pre-extracted DNA samples, highlighting major concerns in the photometric measurements. This situation weakens the evaluation of the extraction phase by considering the Each panel shows a box-plot graph for single measurements (expressed in terms of ng DNA per amplified products) for pre-extracted DNA samples. The box shows the 25th and 75th centiles, the vertical line inside the box indicates the median, and the limits of the 2 arms correspond to the 10th and 90th centiles. Black circles identify laboratories with outlier measurements; white circles identify laboratories with issues of poor performance. E6, sample 3/primer set A; E7, sample 4/primer set A; E8, sample 3/primer set B/lower band product; E9, sample 3/primer set B/upper band product; E10, sample 4/primer set B.
results provided by each participating laboratory for the 2 blood samples included in the EQUAL-qual reagent set. However, because we included the reevaluation of the results of the extracted samples in the central EQUALLaboratory, it was possible to examine the values of Q and R by use of an additional independent and standardized analysis. On the basis of these measurements (Re1, Re2, Qe1, Qe2), 27% of laboratories (46 of 166) had questionable results in terms of quality and/or quantity of DNA derived from blood sample extractions. These results illustrate that the extraction phase remains a critical step for a large number of laboratories performing molecular tests in blood.
From Table 2 and Figs. 1 and 2 , we see a high variability among laboratories with regard to PCR efficiency with both pre-extracted DNA and DNA extracted in house. Because 2 of the DNA samples were preextracted and the primer sets for the PCR amplification were provided, it seems likely that the high variability of performance among laboratories in this regard is associated with the additional reagents (buffers, Taq polymerases, oligonucleotides) as well as the thermal cyclers (20 ) .
To suggest possible corrective actions, it is useful to consider the final results of the PCR-based assay, i.e., the number of bands for each PCR. Table 3 lists 18 laboratories (10%) that reported at least 1 incorrect result in this regard. By comparing the data reported by the participants with those derived from the reevaluation of the PCR products at the EQUAL-Laboratory, we can deduce possible sources of these errors, including transcription errors, mistakes in the electrophoresis interpretation, sample contamination, and low PCR efficiency.
In conclusion, the results of the EQUAL-qual program demonstrate that in a basic experiment for DNA extraction and amplification, based on a predefined protocol and with the availability of some common reagents, we observed high variability between laboratories, and in some cases performances must be considered unsatisfactory. Subsequent to the EQA survey, EQUAL-qual participants identified as having performance issues were invited to participate in 1 of 3 EQUAL training courses in autumn 2005 in Florence, Rome, and Amsterdam. The methodological skills required to improve analytical performance were reviewed during the courses, and participants were invited to carry out the EQUAL-qual survey for a 2nd time. The results of this 2nd survey showed a significant improvement of the performance and will be presented separately.
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